Baidu Acquires GBI to Propel AI-Driven Transformation in Healthcare Industry

“Artificial intelligence has undergone a directional shift, both technically and in terms of commercial applications.” This was the assessment offered by Robin Li, CEO of Baidu, last September at the Shanghai Artificial Intelligence Conference when discussing the latest developments in AI.

Shortly thereafter, the ChatGPT frenzy swept across the globe. On February 7, Baidu announced that its ChatGPT-like product, “ERNIE Bot” (Wenxin Yiyan), would be opened to the public in March following the completion of internal testing. Industry insiders stated that generative AI, spurred by ChatGPT, would usher in a new wave of technological innovation. In fact, the challenge facing high-tech giants lies in leveraging the unique technological advantages of artificial intelligence to empower various industries, align closely with business scenarios, and help different vertical sectors unlock new growth momentum.

In response, Baidu has long had countermeasures in place.Recently, Baidu completed its acquisition of GBI, a global leading one-stop provider of medical informatics data, thereby ushering in a new era of “AI + Intelligent Full-Chain Insights from Medical Big Data.”To disrupt traditional business models for enterprise users in global pharmaceuticals, medical devices, CROs, and healthcare investment, enabling a full-chain “digital-intelligent” transformation spanning “project initiation and R&D, pipeline planning, market access, and commercialization,” thereby promoting the high-quality development of China’s healthcare sector.

After more than two decades of dedicated cultivation, GBI has evolved from a healthcare commercial big data company into an industry-leading provider of healthcare commercial solutions. It is regarded as a trusted, long-term partner of choice by top global pharmaceutical and medical device companies, as well as healthcare investment firms and consulting agencies. In addition to its three global databases that span the entire lifecycle of pharmaceuticals and medical devices—SOURCE Global Drug Database, METRIX Researcher Database, and DEVINT Medical Device Database—GBI is committed to providing global market access intelligence and specialized consulting services to support Chinese enterprises in their global expansion.

Baidu stated that, following the completion of this acquisition, GBI will become a significant asset and key growth engine for Baidu’s Health Care Group (HCG). The strategic alliance between Baidu HCG and GBI heralds a new era for China’s healthcare industry—one in which artificial intelligence breaks down data barriers, disrupts traditional healthcare models, and empowers all stakeholders across the medical sector.

Furthermore, Baidu HCG will continue to provide one-stop health management services, ranging from health education and medical decision support to healthcare services, while offering customized “digital-intelligence” solutions to healthcare institutions and professionals. Baidu Health, a health management platform incubated and developed by Baidu itself, serves 100 million users daily, meeting over 200 million daily user health search queries. It has collaborated with more than 2,200 authoritative experts and teams, covering five major scenarios: health education services, online consultation services, health e-commerce services, internet hospital services, and digital disease-specific alliances. Lingyi Zhihui, leveraging the core AI capabilities of Baidu Brain, offers products and services spanning Clinical Decision Support Systems (CDSS), smart medical records, intelligent cost control for DRG/DIP, single-disease reporting, and in-hospital big data, serving multiple scenarios including clinical practice, management, and scientific research.

By deeply integrating with Baidu HCG’s robust data, technology, and resources, GBI will launch a new business intelligence service segment. Through expert think tanks, patient behavior insights, and comprehensive marketing analytics, it will provide end-to-end commercial decision support covering the entire healthcare industry. Meanwhile, Baidu’s medical NLP and big data governance technologies, refined through extensive application in the healthcare sector, will enhance efficiency across GBI’s entire data pipeline—from data acquisition and governance to precise data search and matching. This will empower pharmaceutical and medical device clients across all stages, including R&D, clinical trials, registration, market access, sales, and investment and financing transactions, comprehensively supporting enterprises in achieving long-term organic growth with sharper insights during their commercial strategic planning.

With the rapid development of China’s pharmaceutical industry, massive amounts of medical information data continue to accumulate. A database that integrates the full lifecycle of drugs and medical devices along with scientific research progress can bring significant commercial value to life and health enterprises and promote the vigorous growth of the healthcare industry. The combination of GBI, which possesses extensive data on pharmaceuticals and medical devices, with Wenxin Yiyan will exert industry-level influence in the field of medical commercial solution services, enabling GBI to become a more comprehensive and intelligently interactive professional think tank for vertical domains. In the future, as GBI deeply integrates with Baidu Health, Lingyi Zhihui, and other core businesses as well as Baidu’s core AI technologies, Baidu HCG will create an artificial intelligence application model tailored for the healthcare industry.

Baidu is a leading AI company with a robust internet foundation. This strategic partnership with GBI undoubtedly enables Baidu to leverage its technological advantages once again, empowering pharmaceutical and medical device enterprises to lead the market in smarter and more efficient ways, benefiting patients and fostering the prosperous development of the healthcare industry ecosystem.

If artificial intelligence is poised to usher in a new wave of technological revolution, Baidu has already geared up and taken the lead.